Personal information

Other IDs

Scopus Author ID: 57202135783

Activities

Collapse all

Works (8)

Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review

International Journal of Molecular Sciences
2025-02-19 | Journal article
DOI: 10.3390/ijms26041760
Contributors: Octavio Ballesta-López; Mayte Gil-Candel; María Centelles-Oria; Juan Eduardo Megías-Vericat; Antonio Solana-Altabella; Hugo Ribes-Artero; Pilar Nos-Mateu; Javier García-Pellicer; José Luis Poveda-Andrés
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Developing a telepharmacy programme with home medication dispensing and informed delivery in a tertiary hospital: description of the model and analysis of the results

European Journal of Hospital Pharmacy
2023-03 | Journal article
DOI: 10.1136/ejhpharm-2021-003194
Contributors: Mayte Gil-Candel; Antonio Solana-Altabella; Esther Vicente-Escrig; Aarón Puplá-Bartoll; Julia Bodega Azuara; Pablo Pérez-Huertas; Raul Ferrando Piqueres
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study

Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
2021 | Journal article
DOI: 10.17235/reed.2020.7124/2020
EID:

2-s2.0-85102212086

Part of ISSN: 11300108
Contributors: Gómez Espín, R.; Nicolás De Prado, I.; Gil Candel, M.; González Carrión, M.; Rentero Redondo, L.; Iniesta Navalón, C.
Source: Self-asserted source
Mayte Gil-Candel via Scopus - Elsevier

Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival

Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
2021 | Journal article
DOI: 10.17235/reed.2021.7638/2020
EID:

2-s2.0-85121958367

Part of ISSN: 11300108
Contributors: Iniesta Navalón, C.; Gil Candel, M.; Salar Valverde, I.; Nicolás de Prado, I.; Gómez Espín, R.; Rentero Redondo, L.
Source: Self-asserted source
Mayte Gil-Candel via Scopus - Elsevier

Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients

Revista Española de Enfermedades Digestivas
2020 | Journal article
DOI: 10.17235/reed.2020.6857/2020
Part of ISSN: 1130-0108
Contributors: Mayte Gil Candel; Juan José Gascón Cánovas; Rosa Gómez Espín; Isabel Nicolás de Prado; Lorena Rentero Redondo; Elena Urbieta Sanz; Carles Iniesta Navalón
Source: Self-asserted source
Mayte Gil-Candel
grade
Preferred source (of 3)‎

Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease

Revista Española de Enfermedades Digestivas
2020 | Journal article
DOI: 10.17235/reed.2020.6618/2019
Part of ISSN: 1130-0108
Contributors: Mayte Gil Candel; Juan José Gascón Cánovas; Elena Urbieta Sanz; Rosa Gómez Espín; Isabel Nicolás de Prado; Carles Iniesta Navalón
Source: Self-asserted source
Mayte Gil-Candel
grade
Preferred source (of 4)‎

Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.

International journal of clinical pharmacy
2020-01-31 | Journal article | Author
DOI: 10.1007/s11096-020-00978-6
PMID: 32006141
Contributors: Mayte Gil-Candel; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Carles Iniesta Navalón
Source: Self-asserted source
Mayte Gil-Candel
grade
Preferred source (of 4)‎

Use of enoxaparin in patients with chronic renal impairment: It is not clear after 25 years of its approval

European Journal of Clinical Pharmacy
2018 | Journal article
EID:

2-s2.0-85047271189

Part of ISSN: 2385409X
Contributors: Gallego Muñoz, C.; Caballero Requejo, M.D.C.; Onteniente Candela, M.; Gil Candel, M.
Source: Self-asserted source
Mayte Gil-Candel via Scopus - Elsevier

Peer review (4 reviews for 2 publications/grants)

Review activity for Farmacia hospitalaria. (3)
Review activity for Pharmacy world & science. (1)
How many people are using ORCID?